Personalized and Precision Medicine Journal

Abstract Rheumatic inflammatory diseases, besides affecting joints and other bodily systems, are linked to heightened mortality and morbidity. Cardiovascular reasons are among the most prevalent mortality factors in individuals with these disorders, attributable to the disease's etiology and pathophysiology, chronic inflammation, and the pharmacological treatments employed. Although rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, and gout exhibit distinct pathophysiology and symptoms, persistent inflammation remains their shared pathophysiological characteristic. Metabolic syndrome has recently been linked to several of these disorders. The investigation of metabolic syndrome in inflammatory rheumatic diseases is significant for multiple reasons, including its correlation with cardiovascular disease onset, the emergence of a pre-inflammatory condition, treatment selection, and associated monitoring. This review article initially explores the significance of metabolic syndrome in rheumatic diseases, followed by a detailed analysis of each condition individually. This study concludes, through a review of previous studies, that abdominal obesity in rheumatoid arthritis and lupus patients, abdominal obesity and hypertension in psoriatic arthritis patients, and hypertriglyceridemia and hypertension in gout are significant elements of metabolic syndrome warranting increased focus.